Wilson Sonsini Goodrich & Rosati represented Forte Biosciences, while Paul Hastings advised TD Cowen in the transaction. Biopharmaceutical company, Forte Biosciences, announced an oversubscribed $53 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Forte Biosciences in the transaction. Forte Biosciences (NASDAQ: FBRX) announced key R&D updates for its product candidate FB-102 (a proprietary molecule...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences on the deal. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...
You must be a Standard 1 Year member to access this content.
